Association of Circulating ACE2 Levels With COVID-19
1 other identifier
observational
261
1 country
1
Brief Summary
COVID-19 cases are rising substantially in Jordan. Since this is a novel virus, there is still much to be investigated surrounding its pathophysiology in order to attempt to find suitable treatments or better decision-making in the prognosis of the disease. This project aims to identify if soluble angiotensin-converting enzyme (ACE2) can be used as a prognostic factor for COVID-19 severity, which will allow clinicians to manage COVID-19 cases more efficiently. ACE2 is of interest since the coronavirus enters host cells through ACE2 receptors. It can slo be hypothesized that the irus may also bind to soluble ACE2, but without mediating its effects. It si, therefore, expected that those with higher levels of ACE2 would more likely have milder disease. This can potentially help improve survival rate, allowing clinicians to identify the higher-risk patients and monitoring them more closely.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 21, 2022
CompletedFirst Submitted
Initial submission to the registry
January 22, 2022
CompletedFirst Posted
Study publicly available on registry
January 25, 2022
CompletedFebruary 8, 2022
January 1, 2022
19 days
January 22, 2022
January 24, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
ACE2 level
Serum level of ACE2 in control and COVID 19 patients will be measured
3 months
Study Arms (2)
Covid-19 Patients
Blood sample from admitted patients will be drawn
Control Patients
Blood sample from control group will be drawn
Interventions
Circulating ACE2 level will be measured
Eligibility Criteria
All adult COVID 19 patients admitted to Jordan University Hospital during 3 months.
You may qualify if:
- Age: 18 and above
- Gender: both males and females.
- Confirmed diagnosis of COVID-19 for patients and confirmed absence of COVID-19
You may not qualify if:
- Healthy individuals: not being diagnosed with COVID-19 or at least has not been in close contact with a person diagnosed with COVID-19.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The University of Jordan
Amman, 11972, Jordan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
January 22, 2022
First Posted
January 25, 2022
Study Start
January 1, 2022
Primary Completion
January 20, 2022
Study Completion
January 21, 2022
Last Updated
February 8, 2022
Record last verified: 2022-01